Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107029 · ClinicalTrials.gov registry record
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
A clinical trial of HIV Infection, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 113
- Enrollment target
- 10
- Study locations
NCT00107029: Completed study of HIV Infection, sponsored by University of North Carolina, Chapel Hill.
NCT00107029 is a study of HIV Infection that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 113 participants, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (53% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00107029, a study of HIV Infection, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 113 participants
- Enrollment target
- 10
- Study locations
Study Summary
This protocol is a study of HIV+ young people who were identified as having certain HIV-1 specific T-cell responses and genetic markers while previously enrolled in the 5-year longitudinal adolescent study, "REACH." Blood samples will be collected, a medical and medication history and physical examination will be performed every 6 months for a total of 2 years.
Primary Outcome
Demonstrate that few CTL escape mutations occur in HIV-1 specific CD8+ T cell epitopes that are HLA-B\*27 and B\*57 restricted, when compared to those restricted by HLA-B\*35 and B\*53.
Conditions Studied
Study Locations (10)
Florida
- Children's Diagnostic and Treatment Center - Fort Lauderdale
- University of Miami-Jackson Memorial Medical Center - Miami
New York
- Mount Sinai Medical Center - New York
- Children's Hospital at Montefiore Medical Center - The Bronx
California
- Children's Hospital of Los Angeles - Los Angeles
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Cook County Children's Hospital - Chicago
Louisiana
- Tulane Medical Center - New Orleans
Maryland
- University of Maryland - Baltimore
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-09 |
What the finished NCT00107029 record still lists
NCT00107029 is an observational study that tracks outcomes without assigning an intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (53% lower).
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 0 interventions.
NCT00107029 lists 10 locations in 8 states (Florida, New York, California).
Frequently Asked Questions
What is clinical trial NCT00107029 about?
NCT00107029 is a clinical study titled "Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth". This protocol is a study of HIV+ young people who were identified as having certain HIV-1 specific T-cell responses and genetic markers while previously enrolled in the 5-year longitudinal adolescent study, "REACH." Blood samples will be collected, a medical and medication history and physical exami...
What is the current status of trial NCT00107029?
This trial is currently completed. The enrollment target is 113 participants. The study started on 2002-12. Estimated completion is 2005-09.
What conditions does trial NCT00107029 study?
This clinical trial studies the following conditions: HIV Infection.
Who is sponsoring clinical trial NCT00107029?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00107029 being conducted?
This trial has 10 study locations across California, District of Columbia, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00107029's enrollment target sits among peer trials
113 23rd of 73 higher than 51 of 73 other HIV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
MAPS PrEP Van Study
RECRUITING · Phase 4
-
HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients
RECRUITING · NA
-
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
RECRUITING · NA
-
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia